AzTrials
AzTrials

OstomyNCT06524401

Novel Post-Surgical Incision Management to Prevent Ostomy Complications

A study testing Limpet in people with Ostomy and Enterocutaneous Fistula, run by HealthPartners Institute at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate the safety and effectiveness of the Limpet, as compared to standard of care ostomy pouches, in reducing complications for ostomy and fistula patients. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ostomy, Enterocutaneous Fistula
What is being tested?
Limpet
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
92 participants
Where
1 siteUnited States
Study dates
18 Nov 2024to Mar 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant is greater than 18 years of age, inclusive
  • Participant is undergoing ileostomy surgery or,
  • has an enterocutaneous fistula with output over 500cc in 24 hours
  • Participants stoma will have a maximum diameter of 1.5 inches based on measurements from the Investigator or Sponsor.
  • Area around the stoma must have no injury through the dermis (i.e., intact skin)
  • Participant is willing and able to comply with all protocol-specified requirements
  • Participant is capable of reading and understanding English and will provide written informed consent to participate.

Who cannot join

  • Unable/unwilling to attend the follow-up appointments
  • Participant has a life expectancy < 30 days.
  • Participant has a stature too small for use of the Limpet in the opinion of the Investigator or Sponsor.
  • Participant has an enteroatmospheric fistula (enteric fistula to an open wound)
  • Participant is scheduling/planning concurrent chemotherapy or other radiation treatment during the study follow-up period
  • Participant has a history of sensitivity or allergy to hydrocolloids or other materials in the Limpet device.
Show all 10Show fewer
  • Participant is pregnant or planning to become pregnant (verbal report).
  • Participant is unable or unwilling to provide informed consent.
  • Participant is currently participating in an investigational drug or another device study that clinically interferes with the current study endpoints.
  • Participant has any other disease or medical condition that, in the opinion of the Investigator or Sponsor, could endanger the participant, interfere with the evaluation of the study device's efficacy or safety, or compromise the participant's ability to comply with/complete the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site, 1 recruiting
  • Regions Hospital

    Saint Paul, Minnesota, 55101

    Allison Kehren, 651-254-5342, Allison.J.Kehren@HealthPartners.Com

    Recruiting

Other trials in United States

About this study

The goal of this clinical trial is to evaluate the safety and effectiveness of the Limpet, as compared to standard of care ostomy pouches, in reducing complications for ostomy and fistula patients. Secondary objectives include evaluating dressing leak rates and causes of complications (e.g., edema, tissue oxygen saturation, and poor stoma eversion). The main questions it aims to answer are:

Primary Hypothesis 1: Peristomal Skin Complications will decrease

Read more

Primary Hypothesis 2: Dressing Leak Rates will decrease

Participants will:

  • Receive either the Limpet device or standard of care adhesive ostomy pouch dressing
  • Return every 7 days for study visits for 30 days to receive device replacement, wound imaging, blood tests, and quality of life surveys.
Read the detailed description

The Limpet is a single-use device intended for effluent management and promotion of healing of intact and injured skin surrounding enterocutaneous fistulae and ostomies.

Our study focuses on small bowel openings, encompassing two important cohorts: 1) ileostomy and 2) enterocutaneous fistulas (ECFs). Our study's success criterion is primarily based on the pooled results from both cohorts.

Primary Hypothesis 1: Peristomal Skin Complications (PSCs): We hypothesize that the Limpet will demonstrate a significant improvement in PSCs compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 35% in PSCs for the pooled cohorts, with a complication rate of 50% in the control group and 15% in the Limpet group.

Primary Hypothesis 2: Dressing Leak Rates: We hypothesize that the Limpet will demonstrate a significant improvement in dressing leak rates compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 15% in leak rates for the pooled cohorts, with a leak rate of 30% in the control group and 15% in the Limpet group.

These hypotheses are grounded in existing literature, supplemented by clinical experience. We intend to conduct subgroup analyses to assess the treatment effect across the two cohorts (ileostomy and ECF) and across other relevant subgroups such as gender, race, etc.

Secondary Hypothesis: Total Complications (PSCs and Stomal Complications): We hypothesize that the Limpet will exhibit a raw difference of 35% in total complications (comprising PSCs and stomal complications like mucocutaneous separation and stoma retraction) for the ileostomy cohort. Stoma complication rates vary widely in the literature, and we plan to conduct sub analyses to evaluate the Limpet's effect on stoma complications independent of PSCs.

This will be a 30 day, single-site, randomized controlled trial (RCT) for a non-significant risk device, Limpet.

The study will have a two-arm parallel group design:

  • Limpet: Participants in this arm will utilize the subject device as intended to be used.
  • Control: Standard treatment with standard of care adhesive ostomy pouches.

Ninety-two participants (78 stoma and 14 enterocutaneous fistula participants) will be randomized after they have consented to study participation. Initial randomization will occur in a 1:1 ratio (Limpet and Control). Participants will be randomly stratified with permuted blocks by BMI (≤ vs > 40) and stoma type (loop ileostomy, end ileostomy, or enterocutaneous fistula) to account differences in healing and wound severity.

This study will be conducted at HealthPartners Institute's Regions Hospital in St. Paul, Minnesota. Data compiled by the Wound, Ostomy, and Continence Nursing Department reveals an annual pool of more than 300 eligible patients at Regions Hospital.

The study will consist of the following visits:

  • Visit C1 (Day -35 to -6): Screening in-person clinic visit
  • Visit C2, Day 1: Baseline appointment clinic visit
  • Visit C3, Week 1: Clinic visit
  • Visit C4, Week 2: Clinic visit
  • Visit C5, Week 3: Clinic visit
  • Visit C6, Week 4: Final appointment during treatment period; clinic visit

After the Baseline Data Collection Period, participants will be randomized by BMI and three stoma types: ileostomy with loop stoma, ileostomy with end stoma, and enterocutaneous fistulas (ECFs) into 1 of 2 treatment groups:

  • Limpet: Participants in this arm will utilize the subject device as intended to be used.
  • Control: Standard treatment with standard of care adhesive ostomy pouches.

On Day 1, Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.

On Day 1, Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.

The brand and model of pumps and adhesive ostomy pouches used by Limpet and Control participants will be recorded for comparison purposes. Participants will return for clinic visits approximately every 7 days to have their device replaced. Participants will have their final study appointment approximately 30 days post-surgery. Clinical support will help the participant troubleshoot dressing problems; and if necessary, bring the patient into the study site for an immediate dressing change.

Being tested
Limpet, Control
Keywords
Stoma, Ileostomy
Medical subject headings
Intestinal Fistula

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • LimpetDevice

    Limpet participants will have their device placed by a clinician. Upon discharge, a portable vacuum pump will be issued to provide negative pressure (e.g., 3M Prevena or Snap; ConvaTec Avelle; or Pensar MicroDoc). These systems are compact, fit in a pocket, are simple to operate, and commonly used in the outpatient setting to provide multiple weeks of therapy. Participants will be furnished with materials to address potential dressing problems while at home: extra waste pouches, adhesive drape strips for sealing air leaks, and standard of care adhesive ostomy pouches and accessories as a backup plan in the event of a Limpet failure.

  • ControlDevice

    Control participants will receive standard of care adhesive ostomy pouch dressings. Participants will be furnished with materials to address potential dressing problems while at home: adhesive ostomy pouches and accessories for pouch replacement. The Control group will change their pouches at home 2 to 5 times per week or more frequently if needed, as per the current standard of care.

Study groups in NCT06524401
Study groupRoleWhat they receive
LimpetExperimentalParticipants in this arm will utilize the subject device as intended to be used.
Receives: Device: Limpet
ControlActive comparatorStandard treatment with standard of care adhesive ostomy pouches.
Receives: Device: Control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Peristomal Skin Complications (PSCs)

    We hypothesize that the Limpet will demonstrate a significant improvement in PSCs compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 35% in PSCs for the pooled cohorts, with a complication rate of 50% in the control group and 15% in the Limpet group.

    Measured: 30 days

  2. Dressing Leak Rates

    We hypothesize that the Limpet will demonstrate a significant improvement in dressing leak rates compared to standard of care adhesive ostomy pouches. Specifically, we anticipate a raw difference of 15% in leak rates for the pooled cohorts, with a leak rate of 30% in the control group and 15% in the Limpet group.

    Measured: 30 Days

Secondary outcomes (1)
  1. Total Complications (PSCs and Stomal Complications)

    We hypothesize that the Limpet will exhibit a raw difference of 35% in total complications (comprising PSCs and stomal complications like mucocutaneous separation and stoma retraction) for the ileostomy cohort. Stoma complication rates vary widely in the literature, and we plan to conduct sub analyses to evaluate the Limpet's effect on stoma complications independent of PSCs.

    Measured: 30 Days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2024
  2. Study start18 Nov 2024
  3. Primary completionJan 2029 (estimated)
  4. Study completionMar 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
92 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06524401
Sponsor's protocol ID
A22-066
Status last verified
Oct 2026
First submitted
23 Jul 2024
Last updated
20 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data will not be shared with external entities outside of aggregate form for publication. Deidentified data will be shared with the study sponsor. Study identifiers will be destroyed after publication.

Questions about this trial

What is this clinical trial studying?

A study testing Limpet in people with Ostomy and Enterocutaneous Fistula, run by HealthPartners Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Allison Kehren (651-254-5342, Allison.J.Kehren@HealthPartners.Com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Peristomal Skin Complications (PSCs) (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in